Eurostars grants the development and test of an innovative non-invasive trace gas analyser-platform targeting cancer diagnostics.
The primary objective of the NxPAS project is the development and test of a non-invasive trace gas analyser-platform targeting the major market opportunity of medical diagnostics based on exhaled breath analysis. The final device will be applied to exhaled human breath for screening early stages of health problems – instantly providing data allowing diagnostics of various diseases, including several cancer types in special patients group.
The technology behind the NxPAS-platform is an innovative photoacoustic spectroscopy gas sensor, integrated with advanced solid-state laser sources. NxPAS will provide fast screening capability that will significantly improve early disease diagnosis for the benefit of patients and reduce medical expenses, thus significantly improve cost efficiency compared to existing state-of-the-art products.
With the support from Eurostars the consortium behind NxPAS will develop all sub-technologies and integrate the final device. Finally, prototype testing and data acquisition will be carried out with patients through small-scale clinical trials at Université de Liège.